Predicting the evolution of antibiotic resistance
© Schenk and de Visser; licensee BioMed Central Ltd. 2012
Received: 4 February 2013
Accepted: 15 February 2013
Published: 22 February 2013
Mutations causing antibiotic resistance are often associated with a cost in the absence of antibiotics. Surprisingly, a new study found that bacteria adapting to increased temperature became resistant to rifampicin. By studying the consequences of the involved mutations in different conditions and genetic backgrounds, the authors illustrate how knowledge of two fundamental genetic properties, pleiotropy and epistasis, may help to predict the evolution of antibiotic resistance.
See research article http://www.biomedcentral.com/1471-2148/13/50
The spread of pathogenic bacteria that are resistant to certain antibiotics constitutes a growing threat to public health. One strategy to counter this problem is to minimize the probability that antibiotic resistance arises. To achieve this we need to understand the factors that drive and constrain its evolution . The fitness costs associated with resistance have received considerable attention since they determine the long-term success of resistant bacteria. Such costs may arise from modifications of cellular components with vital functions, such as ribosomes or the cell wall, or from metabolic costs due to the expression of enzymes that break down the antibiotic. These pleiotropic costs would allow resistance to be selected only when bacteria are confronted with antibiotics. Surprisingly, a study published in BMC Evolutionary Biology  now reports the fixation of mutations causing rifampicin resistance in Escherichia coli populations that evolved at high temperature in medium without any antibiotics. By gauging the fitness consequences of these mutations in other environments and in other bacterial strains, the authors show that the beneficial effects of these mutations are highly specific and highlight two factors that are crucial for the evolution of antibiotic resistance: pleiotropy and epistasis.
The study by Rodríguez-Verdugo et al.  analyses E. coli lines from a previously reported large-scale evolution experiment with 114 populations that have evolved for 2,000 generations at an increased temperature of 42.2°C . Genome sequencing of clones from all evolved populations showed that 74 clones contained at least one of 46 unique non-synonymous mutations in the rpoB gene , which encodes the β-subunit of RNA polymerase and is a known target of rifampicin resistance . Thirteen of the 114 lines did acquire intermediate to very high levels of rifampicin resistance. Interestingly, all 13 resistant lines had a non-synonymous mutation in rpoB, and 12 showed one of three mutations at codon position 572, thus showing signatures of parallel evolution - a hallmark of their involvement in adaptation. By looking at the temporal dynamics the researchers showed that these mutations appeared early in the selection, again consistent with their involvement in adaptation. The authors obtained definitive proof that the three mutations at position 572 increase fitness in the evolutionary environment by testing their effect in the ancestral strain, revealing fitness increases of about 20%.
How surprising are these results? Resistance mechanisms are generally thought to be costly since antibiotics target fundamental cellular processes, including the synthesis of mRNA, proteins and cell structures . Fitness costs associated with resistance may arise from modifications in the cellular targets of antibiotics, which prevent binding of the drug but also compromise their cellular role. This is, for instance, the case for resistance to rifampicin and streptomycin, which target the β-subunit of RNA polymerase and ribosomal protein S12, respectively. Costs may also be due to the synthesis of enzymes that break down antibiotics, as is the case for β-lactams, or when porin mutations that interfere with the antibiotic entering the cell also limit the uptake of nutrients, as for penicillin and tetracycline. Many studies have quantified such costs in the absence of the antibiotic under various in vitro and in vivo conditions . But a 'cost of resistance' was not always observed, and neutral or even beneficial effects in the absence of the drug have previously been observed for resistance to a number of other antibiotics (reviewed in ). Complementary to the results of Rodríguez-Verdugo et al., a recent study showed that E. coli selected in the presence of rifampicin acquired mutations in the rpoB gene that were beneficial in minimal medium at increased temperature . However, other than the study by Rodríguez-Verdugo et al., these studies lacked genomic information and could not rule out the possibility that secondary mutations have occurred that compensated for the negative pleiotropic effects of the resistance mutations.
Pleiotropy and epistasis
Epistasis, the non-additive interaction of mutations at multiple loci, plays a major role when resistance to antibiotics requires the sequential substitution of multiple mutations. Sign epistasis - which occurs when mutations are beneficial in one background and deleterious in other backgrounds - introduces particularly strong constraints. It reduces the number of mutational pathways leading from sensitive to highly resistant mutants that are accessible to natural selection , thereby making evolution more predictable. Mutational pathways can be visualized on fitness landscapes, where fitness is mapped onto genotypes carrying all possible combinations of a set of mutations that contribute to adaptation. In theory, with full knowledge of the fitness landscape one should be able to predict the most likely path leading to full antibiotic resistance under any given condition; such predictions may be extended to other conditions with knowledge of the pleiotropic effects of the mutations (Figure 1b). Even for a single condition, full knowledge of the fitness landscape is, however, unrealistic, because the number of combinations grows exponentially with the number of contributing mutations. Current attempts to study empirical fitness landscapes by systematically analysing mutants carrying all possible combinations of sets of interesting mutations  are therefore necessarily restricted to sets of a handful of mutations. A complicating factor is that the predictability of evolution not only depends on knowledge of the fitness landscape, but also on population dynamic variables, such as population size and mutation rate, which determine which of the possible pathways will actually be followed .
The prospect of predicting the evolution of antibiotic resistance may seem utopic, but it is gaining momentum. One stimulus is the growing number of observations of the repeated fixation of the same small set of resistance mutations in independently evolving populations , to which the study of Rodríguez-Verdigo et al.  can now be added. A growing number of evolutionary biologists use antibiotic resistance as an experimental system. The information on the molecular changes involved in antibiotic resistance that will result from these endeavors will feed models of evolution that can incorporate observed patterns of pleiotropy and epistasis and explore the consequences under various population dynamic scenarios. With the aid of such models, we can start predicting what will happen when we expose pathogens to antibiotics, raising the prospect of devising strategies to reduce the probability that antibiotic resistance will arise. However, let us not be too optimistic: while we may be able to predict what happens when an antibiotic is present under controlled conditions in the laboratory, it will be even more challenging to predict how resistance develops under conditions that are unpredictable themselves.
We acknowledge funding from the Deutsche Forschungsgemeinschaft within SFB 680 'Molecular Basis of Evolutionary Innovations' and comments from Duur Aanen.
- Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI: Tackling antibiotic resistance (Essay). Nat Rev Microbiol. 2011, 9: 894-896. 10.1038/nrmicro2693.PubMed CentralView ArticlePubMed
- Rodríguez-Verdugo A, Gaut BS, Tenaillon O: Evolution of Escherichia coli rifampicin resistance in an antibiotic-free environment during thermal stress. BMC Evol Biol. 2013, 13: 50-PubMed CentralView ArticlePubMed
- Tenaillon O, Rodríguez-Verdugo A, Gaut RL, McDonald P, Bennett AF, Long AD, Gaut BS: The molecular diversity of adaptive convergence. Science. 2012, 335: 457-461. 10.1126/science.1212986.View ArticlePubMed
- Andersson DI, Hughes D: Antibiotic resistance and its cost: is it possible to reverse resistance?. Nat Rev Microbiol. 2010, 8: 260-271.PubMed
- Trindade S, Sousa A, Gordo I: Antibiotic resistance and stress in the light of Fisher's model. Evolution. 2012, 66: 3815-3824. 10.1111/j.1558-5646.2012.01722.x.View ArticlePubMed
- Orr HA: The probability of parallel evolution. Evolution. 2005, 59: 216-220.View ArticlePubMed
- Schenk MF, Szendro IG, Krug J, de Visser JAGM: Quantifying the adaptive potential of an antibiotic resistance enzyme. PLoS Genet. 2012, 8: e1002783-10.1371/journal.pgen.1002783.PubMed CentralView ArticlePubMed
- Weinreich DM, Delaney NF, DePristo MA, Hartl DL: Darwinian evolution can follow only very few mutational paths to fitter proteins. Science. 2006, 312: 111-114. 10.1126/science.1123539.View ArticlePubMed
- Szendro IG, Schenk MF, Franke J, Krug J, De Visser JAGM: Quantitative analyses of empirical fitness landscapes. J Stat Mechanics. 2013, P01005-
- Szendro IG, Franke J, De Visser JAGM, Krug J: Predictability of evolution depends non-monotonically on population size. Proc Natl Acad Sci USA. 2013, 110: 571-576. 10.1073/pnas.1213613110.PubMed CentralView ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.